Affiliated to the Functional Imaging Unit via employment at Center for Neuropsychiatric Schizophrenia Research (CNSR) & Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research (CINS). 

Investigator in a doubleblinded, randomized placebocontrolled study “Treatment of antipsychotic-associated obesity with a GLP-1-analogue” – The TAO study.  

The study aims to find a medical treatment against the pro-metabolic side effects and weightgain observed in antipsychotic-treated patients.

The TAO study investigates the physiological effects of the GLP-1-analoque (exenatide) in obese, nondiabetic schizophrenia patients. 

The primary endpoint is weight loss after 12 weeks treatment. Secondary endpoints comprise potential brain structural- and volumetric changes with hippocampus and striatum as regions of interest. Moreover changes in cerebral blood flow especially frontal cortex will be investigated and correlated to potential improvement in cognition.